Strategic Partnerships Recent high-profile collaborations such as the Fred Hutchinson Cancer Center study highlight Reaction Biology as a reliable partner for complex drug discovery programs and translational research, signaling opportunity to pursue co-development or contract research collaborations with leading academic and research institutions.

Expanded Leadership New executive appointments in 2022 including CCO and CPO, along with a CFO, suggest a growth-driven strategy and readiness to scale client programs, enterprise deals, and formalized commercial processes that can be leveraged in enterprise account outreach.

Broad Capabilities A wide discovery and development portfolio from protein production to in vivo, plus access to a large library of validated drug targets and cell lines, positions RBC as a one-stop-shop for early-stage drug discovery needs, appealing to teams seeking integrated solutions.

Global Footprint Strategically located facilities in the US and EU enable streamlined operations, faster turnaround times, and secure handling of sensitive materials, a selling point for multinational pharma and biotechs requiring cross-border collaborations and compliant workflows.

Strong Track Record A history of serving over 2,000 clients across thousands of projects annually, with experience supporting FDA and other global regulatory programs, provides credibility for pursuing larger, multi-project or multi-year engagements with mid-to-large biotech companies.